Related Experiment Video
Updated: Sep 27, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Modern issues of improving the prognosis in patients with atrial fibrillation after ischemic stroke]
O D Ostroumova1, T M Ostroumova2, A V Arablinsky3
1Russian Medical Academy of Continuous Professional; I.M. Sechenov First Moscow State Medical University.
Insights
Direct oral anticoagulants like rivaroxaban are effective for preventing recurrent stroke in atrial fibrillation (AF) patients. Rivaroxaban offers advantages in efficacy, safety, and patient compliance for secondary stroke prevention.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation (AF) increases stroke risk, necessitating effective anticoagulant therapy.
- Direct oral anticoagulants (DOACs) are recommended for stroke prevention in AF.
- Evidence supports rivaroxaban's efficacy and safety in secondary stroke prevention.
Purpose of the Study:
- To evaluate the advantages of rivaroxaban for secondary stroke prevention in AF patients.
- To assess rivaroxaban's role in improving prognosis through stroke prevention, kidney disease management, and atherosclerosis control.
- To highlight rivaroxaban's benefits regarding patient compliance due to once-daily dosing.
Main Methods:
- Review of extensive evidence-based databases comparing DOACs.
- Analysis of clinical guidelines recommending anticoagulant therapy for AF.
- Assessment of rivaroxaban's safety profile and impact on comorbidities.
Main Results:
- Rivaroxaban demonstrates significant advantages over other DOACs in secondary stroke prevention for AF.
- Rivaroxaban offers an optimal safety profile.
- Benefits include stroke recurrence prevention, reduced kidney disease progression, and slowed vascular atherosclerosis.
Conclusions:
- Rivaroxaban is a preferred choice for secondary stroke prevention in AF patients.
- Its once-daily dosing improves compliance, especially in patients with cognitive disorders.
- Rivaroxaban offers a favorable prognosis by addressing multiple aspects of AF-related complications.
Abstract:
The anticoagulant therapy with a priority of direct oral anticoagulants is an approach to the prevention of recurrent stroke in patients with atrial fibrillation (AF) that has presently proved its efficacy and is stated in international clinical guidelines. An extensive evidence-based database demonstrates advantages of rivaroxaban over other drugs of this class in secondary prevention of stroke in AF. Furthermore, these advantages are combined with the optimal safety profile. The rivaroxaban treatment may provide the most favorable prognosis due to the prevention of recurrent stroke in AF, reducing the rate of kidney disease progression, and slowing vascular atherosclerosis. An important beneficial feature of rivaroxaban is once-a-day intake, which is important in the context of a high incidence of cognitive disorders in this patient category, and may improve their compliance and, thus, help achieving the expected profile of treatment efficacy. Thus, rivaroxaban can be regarded as a drug of choice for secondary prevention of stroke in AF.
Related Concept Videos
Atherosclerosis IV: Nursing Management
Acute Coronary Syndrome IV: Interprofessional Care
Atherosclerosis III: Management
Aortic Regurgitation III: Medical Management
Heart Failure V: Medical Management
Cardiomyopathy V: Interprofessional Care

